DNA Damage Response Deficiency Assay predicts response to treatment in ovarian cancer
Ovarian cancer is the leading cause of death from gynaecological malignancies. The standard first line therapy is a combination of carboplatin and paclitaxel and has a response rate of 70%-80%, although the majority relapse. Almac have previously developed a 44 transcript DNA damage response deficiency (DDRD) assay which indicates loss of the FA/BRCA pathway and predicts response to DNA damaging agents.
In this study we have investigated the utility of the DDRD assay predicting response to platinum based therapy in ovarian cancer.